International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy

被引：171

作者：

Cardoso, Fatima ^{[1
]}

Bedard, Philippe L. ^{[1
]}

Winer, Eric P. ^{[2
]}

Pagani, Olivia ^{[3
,4
]}

Senkus-Konefka, Elzbieta ^{[5
]}

Fallowfield, Lesley J. ^{[6
]}

Kyriakides, Stella ^{[7
]}

Costa, Alberto ^{[8
,9
]}

Cufer, Tanja ^{[10
]}

Albain, Kathy S. ^{[11
]}

机构：

[1] Inst Jules Bordet, Med Oncol & Translat Res Unit, Dept Med Oncol, B-1000 Brussels, Belgium

[2] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol,Brigham & Womens Hosp, Boston, MA 02115 USA

[3] Osped Italiano, Dept Med Oncol, Oncol Inst So Switzerland, Lugano, Switzerland

[4] Switzerland & Swiss Grp Clin Canc Res, Bern, Switzerland

[5] Med Univ Gdansk, Dept Radiotherapy & Oncol, Gdansk, Poland

[6] Univ Sussex, Dept Psychooncol, Brighton & Sussex Med Sch, Brighton BN1 9RH, E Sussex, England

[7] European Breast Canc Coalit, Nicosia, Cyprus

[8] European Sch Oncol, Milan, Italy

[9] Maugeri Fdn Breast Unit, Pavia, Italy

[10] Univ Clin Golnik, Dept Med Oncol, Golnik, Slovenia

[11] Loyola Univ, Dept Med Oncol, Chicago Stritch Sch Med, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA

来源：

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2009年 / 101卷 / 17期

关键词：

RANDOMIZED PHASE-III; ADVANCED COLORECTAL-CANCER; CAPECITABINE PLUS DOCETAXEL; 1ST-LINE THERAPY; LINE THERAPY; TRIAL; PACLITAXEL; ANTHRACYCLINE; SURVIVAL; DOXORUBICIN;

D O I：

10.1093/jnci/djp235

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Compared with treatment options for early-stage breast cancer, few data exist regarding the optimal use of chemotherapy for metastatic breast cancer (MBC). The choice of using a combination of cytotoxic chemotherapies vs sequential single agents is controversial. At the 6th European Breast Cancer Conference, the European School of Oncology Metastatic Breast Cancer Task Force convened an open debate on the relative benefits of combination vs sequential therapy. Based on the available data, the Task Force recommends sequential monotherapy as the preferred choice in advanced disease, in the absence of rapid clinical progression, life-threatening visceral metastases, or the need for rapid symptom and/or disease control. Patient- and disease-related factors should be used to choose between combination and sequential single-agent chemotherapy for MBC. Additional research is needed to determine the impact of therapy on patient-rated quality of life and to identify predictive factors that can be used to guide therapy.

引用

页码：1174 / 1181

页数：8

共 57 条

[1]

Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0

[2]

Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer:: A Spanish breast cancer research group (GEICAM-9903) phase III study [J].

Alba, E ;

Martín, M ;

Ramos, M ;

Adrover, E ;

Balil, A ;

Jara, C ;

Barnadas, A ;

Fernández-Aramburo, A ;

Sánchez-Rovira, P ;

Amenedo, M ;

Casado, A .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (13) :2587-2593

[3]

Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment [J].

Albain, Kathy S. ;

Nag, Shona M. ;

Calderillo-Ruiz, German ;

Jordaan, Johann P. ;

Llombart, Antonio C. ;

Pluzanska, Anna ;

Rolski, Janusz ;

Melemed, Allen S. ;

Reyes-Vidal, Jose M. ;

Sekhon, Jagdev S. ;

Simms, Lorinda ;

O'Shaughnessy, Joyce .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (24) :3950-3957

[4]

ANDERSSON M, 1986, CANCER TREAT REP, V70, P1181

[5]

Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: Final results of a phase III study with a factorial design [J].

Berruti, A ;

Bitossi, R ;

Gorzegno, G ;

Bottini, A ;

Alquati, P ;

De Matteis, A ;

Nuzzo, F ;

Giardina, G ;

Danese, S ;

De Lena, M ;

Lorusso, V ;

Farris, A ;

Sarobba, MG ;

DeFabiani, E ;

Bonazzi, G ;

Castiglione, F ;

Bumma, C ;

Moro, G ;

Bruzzi, P ;

Dogliotti, L .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (20) :4150-4159

[6]

Second consensus on medical treatment of metastatic breast cancer [J].

Beslija, S. ;

Bonneterre, J. ;

Burstein, H. ;

Cocquyt, V. ;

Gnant, M. ;

Goodwin, P. ;

Heinemann, V. ;

Jassem, J. ;

Koestler, W. J. ;

Krainer, M. ;

Menard, S. ;

Petit, T. ;

Petruzelka, L. ;

Possinger, K. ;

Schmid, P. ;

Stadtmauer, E. ;

Stockler, M. ;

Van Belle, S. ;

Vogel, C. ;

Wilcken, N. ;

Wiltschke, C. ;

Zielinski, C. C. ;

Zwierzina, H. .

ANNALS OF ONCOLOGY, 2007, 18 (02) :215-225

[7]

Beslija S, 2006, J CLIN ONCOL, V24, p20S

[8]

Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer [J].

Bishop, JF ;

Dewar, J ;

Toner, GC ;

Smith, J ;

Tattersall, MHN ;

Olver, IN ;

Ackland, S ;

Kennedy, I ;

Goldstein, D ;

Gurney, H ;

Walpole, E ;

Levi, J ;

Stephenson, J ;

Canetta, R .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) :2355-2364

[9]

Gemcitabine as first-line therapy in patients with metastatic breast cancer: A phase II trial [J].

Blackstein, M ;

Vogel, CL ;

Ambinder, R ;

Cowan, J ;

Iglesias, J ;

Melemed, A .

ONCOLOGY, 2002, 62 (01) :2-8

[10]

Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure [J].

Bonneterre, J ;

Roché, H ;

Monnier, A ;

Guastalla, JP ;

Namer, M ;

Fargeot, P ;

Assadourian, S .

BRITISH JOURNAL OF CANCER, 2002, 87 (11) :1210-1215

← 1 2 3 4 5 6 →